Amylyx Pharmaceuticals, Inc. 4

Co‑Chief Executive Officer Justin B. Klee sold 30,464 shares of Amylyx Pharmaceuticals, Inc. common stock on September 10, 2026 to cover taxes from vested performance stock units.

On September 10, 2026, Amylyx Pharmaceuticals, Inc. Co‑Chief Executive Officer Justin B. Klee sold a total of 30,464 shares of Amylyx common stock in two market transactions at weighted average prices of $32.1293 and $33.1552 per share, respectively. These sales were executed solely to satisfy tax withholding obligations arising from the vesting of performance stock units and were automatic, not discretionary. Following the transactions, Klee continued to hold 3,613,056 shares of Amylyx common stock directly, indicating that the sales represented a small fraction of his overall ownership stake.

Filing Facts

CIK

1658551

Ticker

AMLX

Form

4

Source Type

fda

Accession

0001193125-26-390506

Alert Tier

5